Abstract
Novuspharma is developing pixantrone, a second-generation, well-tolerated anthracenedione analog, for the potential treatment of lymphoma and multiple sclerosis.
MeSH terms
-
Animals
-
Hematologic Neoplasms / drug therapy
-
Humans
-
Isoquinolines / chemistry
-
Isoquinolines / therapeutic use*
-
Technology, Pharmaceutical / legislation & jurisprudence
-
Technology, Pharmaceutical / methods*
-
Technology, Pharmaceutical / trends
-
Topoisomerase II Inhibitors
Substances
-
Isoquinolines
-
Topoisomerase II Inhibitors
-
pixantrone